- Home
- GOCO vs PRLD Comparison
GOCO vs PRLD Comparison
Compare GOCO & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOCO
- PRLD
- Stock Information
- Founded
- GOCO 2001
- PRLD 2016
- Country
- GOCO United States
- PRLD United States
- Employees
- GOCO N/A
- PRLD N/A
- Industry
- GOCO Specialty Insurers
- PRLD Medicinal Chemicals and Botanical Products
- Sector
- GOCO Finance
- PRLD Health Care
- Exchange
- GOCO Nasdaq
- PRLD Nasdaq
- Market Cap
- GOCO 64.9M
- PRLD 69.1M
- IPO Year
- GOCO 2020
- PRLD 2020
- Fundamental
- Price
- GOCO $4.33
- PRLD $1.26
- Analyst Decision
- GOCO Hold
- PRLD Strong Buy
- Analyst Count
- GOCO 1
- PRLD 3
- Target Price
- GOCO $12.00
- PRLD $4.00
- AVG Volume (30 Days)
- GOCO 43.5K
- PRLD 311.7K
- Earning Date
- GOCO 11-06-2025
- PRLD 11-05-2025
- Dividend Yield
- GOCO N/A
- PRLD N/A
- EPS Growth
- GOCO N/A
- PRLD N/A
- EPS
- GOCO N/A
- PRLD N/A
- Revenue
- GOCO $822,444,000.00
- PRLD $7,000,000.00
- Revenue This Year
- GOCO $2.06
- PRLD N/A
- Revenue Next Year
- GOCO $5.47
- PRLD N/A
- P/E Ratio
- GOCO N/A
- PRLD N/A
- Revenue Growth
- GOCO 17.46
- PRLD N/A
- 52 Week Low
- GOCO $4.31
- PRLD $0.61
- 52 Week High
- GOCO $21.00
- PRLD $2.01
- Technical
- Relative Strength Index (RSI)
- GOCO 35.18
- PRLD 50.03
- Support Level
- GOCO $4.32
- PRLD $1.15
- Resistance Level
- GOCO $4.97
- PRLD $1.50
- Average True Range (ATR)
- GOCO 0.26
- PRLD 0.21
- MACD
- GOCO -0.00
- PRLD -0.02
- Stochastic Oscillator
- GOCO 3.75
- PRLD 27.01
About GOCO GoHealth Inc.
GoHealth Inc is a health insurance marketplace and Medicare-focused digital health company whose purpose is to compassionately ensure consumers' peace of mind when making healthcare decisions so consumers can focus on living life. It offers Medicare plans, including, but not limited to, Medicare Advantage, Medicare Supplement and prescription drug plans. Its proprietary technology platform leverages modern machine-learning algorithms, powered by over two decades of insurance purchasing behavior, to reimagine the process of matching a health plan to a consumer's specific needs.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.